News provided by Novo Nordisk Jul 01, 2026, 07:00 ET Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity
Consmelo a diario y complemntalo con una alimentacin saludable
It is designed as a once-weekly injectable treatment for obesity, working via amylin receptors rather than the GLP-1 pathway used by most current weight loss medications
Contrary to the decrease in HbA1c values that attained a plateau after 24 weeks, weight reduction with retatrutide continued to progress to the end of follow-up at 36 weeks [4]
Proper storage in a cool and dry environment is recommended to maintain peptide integrity
Microorganisms 11 , 1516 (2023)
